MedTrace Logo

Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder

NCT00533117 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2024-01-05

Study results available
· View outcomes & findings →

Summary

This study will determine whether dialectical behavior therapy and fluoxetine are more effective combined or alone in treating people with borderline personality disorder.

Conditions

  • Borderline Personality Disorder

Interventions

DRUG

Fluoxetine

Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated

BEHAVIORAL

Dialectical Behavior Therapy

Dialectical Behavior Therapy is a form of CBT originally developed to treat suicidal and self injuring individuals with borderline personality disorder. Treatment consists of 2 sessions/week: individual psychotherapy and skills training group.

BEHAVIORAL

Supportive psychotherapy

Supportive therapy is a manualized form of psychotherapy designed to enhance individual's strengths and coping mechanisms while reducing distress.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Barbara Stanley, PhD · Research Foundation for Mental Hygiene/Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-31
Primary Completion
2008-01-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00533117 on ClinicalTrials.gov